Theriva Biologics (TOVX) Stock Price, News & Analysis

Company Overview

Theriva Biologics, Inc. is a clinical-stage biotechnology company focused on developing therapies that target the microbiome and tumor microenvironment. Its programs are designed to address serious diseases by using engineered biological products and other approaches intended to improve treatment outcomes.

The company’s development pipeline includes VCN-01, an oncolytic adenovirus being investigated for use in pancreatic ductal adenocarcinoma, as well as microbiome-focused candidates such as SYN-004 (ribaxamase) and SYN-020. Ribaxamase is an orally administered enzyme designed to break down certain beta-lactam antibiotics in the gastrointestinal tract and potentially reduce disruption of the gut microbiome. SYN-020 is an oral intestinal alkaline phosphatase program being studied for conditions associated with intestinal and systemic inflammation.

Theriva Biologics was formerly known as AzurRx BioPharma, Inc. and adopted its current name as it expanded its focus on microbiome-based and oncolytic therapies. The company is headquartered in the United States and conducts development activities through clinical research and collaborations. Steven A. Shallcross serves as chief executive officer.

Key Stats

• Today's Range: $0.20 to $0.22
• 50-Day Range: $0.20 to $0.25
• 52-Week Range: $0.16 to $0.85
• Volume: 708,742 shs
• Average Volume: 502,203 shs
• Market Capitalization: $6.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Buy

Theriva Biologics Stock Analysis - MarketRank™

Theriva Biologics scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Theriva Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Theriva Biologics has a consensus price target of $1.00, representing about 408.6% upside from its current price of $0.20.

Amount of Analyst Coverage

Theriva Biologics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Theriva Biologics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Theriva Biologics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Theriva Biologics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.13% of the float of Theriva Biologics has been sold short.

Short Interest Ratio / Days to Cover

Theriva Biologics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Theriva Biologics has recently increased by 7.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Theriva Biologics does not currently pay a dividend.

Dividend Growth

Theriva Biologics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for TOVX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Theriva Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.02% of the stock of Theriva Biologics is held by insiders.

Percentage Held by Institutions

6.17% of the stock of Theriva Biologics is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:TOVX
• CIK: 894158
• Web: therivabio.com
• Phone: (734) 332-7800
• Fax: 301-417-4367
• Employees: 16
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Theriva Biologics: $1.00
• High Price Target: $1.00
• Low Price Target: $1.00
• Potential Upside/Downside: +408.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($33.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.74 million
• Net Margins: N/A
• Pretax Margin: -3,872.67%
• Return on Equity: -93.49%
• Return on Assets: -32.69%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 1.13
• Quick Ratio: 1.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.46 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 33,740,000
• Free Float: 33,396,000
• Market Cap: $6.63 million
• Optionable: Not Optionable
• Beta: 1.19